FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma

Food and Drug Administration approved cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma. February 9, 2021. More Information https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA